Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.

•Cervarix® demonstrated, in clinical trials, an overall 93.2% efficacy against CIN3+.•This efficacy translates into a large number of lives saved in all countries; an additional 18–34% more lives saved than expected based on protection against HPV-16/18 only.•Public health benefit also includes reduction in costs, morbidity and suffering.